Brentuximab vedotin (Adcetris®) is a targeted cancer medicine approved by the U.S. Food and Drug Administration (FDA) to treat adult patients with certain types of lymphoma including Hodgkin lymphoma, systemic anaplastic large cell lymphoma (ALCL), and other CD30-expressing lymphomas. It is administered as an intravenous (IV) infusion. Brentuximab vedotin is a monoclonal antibody-drug conjugate (ADC) that works by targeting and destroying cancer cells. It is composed of an antibody (cAC10) that binds to a protein (CD30) found on the surface of cancer cells, and a chemotherapy drug (monomethyl auristatin E or MMAE). The antibody binds to the cancer cells, carrying the chemotherapy drug directly to them. This allows for a higher concentration of chemotherapy drug in the cancer cells, destroying them while minimizing damage to healthy cells.
Brentuximab vedotin, also known by its brand name Adcetris, is a medication used to treat several types of lymphoma, a cancer of the lymphatic system. Here's a breakdown of its key aspects:
What it treats:
- Hodgkin lymphoma: This is a type of lymphoma affecting the white blood cells called lymphocytes. Brentuximab vedotin is used in various stages of Hodgkin lymphoma, including newly diagnosed, relapsed, and post-transplant cases.
- Anaplastic large cell lymphoma (ALCL): This is another type of lymphoma that can develop in different parts of the body. Brentuximab vedotin is used to treat specific subtypes of ALCL, including systemic ALCL and primary cutaneous ALCL (affecting the skin).
- Other lymphomas: In some cases, it may be used for other types of lymphomas, such as peripheral T-cell lymphoma and mycosis fungoides (a type of T-cell lymphoma affecting the skin).
How it works:
- Brentuximab vedotin is classified as an antibody-drug conjugate (ADC).
- It consists of two parts:
- Monoclonal antibody: This part targets a specific protein called CD30, which is present on the surface of many lymphoma cells.
- Cytotoxic drug (monomethyl auristatin E, MMAE): This drug is attached to the antibody and is designed to kill cancer cells.
- When the medication is administered, the antibody seeks out and binds to the CD30 protein on lymphoma cells. This delivers the MMAE directly to the cancer cells, leading to their death.
How it's administered:
- Brentuximab vedotin is typically given as an intravenous (IV) infusion over 30 minutes.
- The specific dosing schedule and duration of treatment depend on the type and stage of lymphoma being treated.
Important considerations:
- Brentuximab vedotin can cause various side effects, including fatigue, peripheral neuropathy (tingling or numbness in the hands and feet), nausea, vomiting, and low blood cell counts.
- It is important to disclose all medical conditions and medications you are taking to your doctor before starting treatment with brentuximab vedotin, as there can be potential interactions with other drugs.
- Pregnancy and breastfeeding are not recommended while using this medication.
Disclaimer: This information is provided for general knowledge only and should not be a substitute for professional medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment specific to your situation.